- Home
- KE vs ATXS Comparison
KE vs ATXS Comparison
Compare KE & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KE
- ATXS
- Stock Information
- Founded
- KE 1961
- ATXS 2008
- Country
- KE United States
- ATXS United States
- Employees
- KE N/A
- ATXS N/A
- Industry
- KE Electrical Products
- ATXS Biotechnology: Pharmaceutical Preparations
- Sector
- KE Technology
- ATXS Health Care
- Exchange
- KE Nasdaq
- ATXS Nasdaq
- Market Cap
- KE 467.2M
- ATXS 516.4M
- IPO Year
- KE N/A
- ATXS 2015
- Fundamental
- Price
- KE $19.17
- ATXS $7.50
- Analyst Decision
- KE Buy
- ATXS Strong Buy
- Analyst Count
- KE 5
- ATXS 5
- Target Price
- KE $22.60
- ATXS $25.60
- AVG Volume (30 Days)
- KE 117.3K
- ATXS 368.6K
- Earning Date
- KE 02-03-2025
- ATXS 03-03-2025
- Dividend Yield
- KE N/A
- ATXS N/A
- EPS Growth
- KE N/A
- ATXS N/A
- EPS
- KE 0.50
- ATXS N/A
- Revenue
- KE $1,650,685,000.00
- ATXS N/A
- Revenue This Year
- KE N/A
- ATXS N/A
- Revenue Next Year
- KE $3.66
- ATXS N/A
- P/E Ratio
- KE $38.30
- ATXS N/A
- Revenue Growth
- KE N/A
- ATXS N/A
- 52 Week Low
- KE $16.64
- ATXS $6.96
- 52 Week High
- KE $25.22
- ATXS $16.90
- Technical
- Relative Strength Index (RSI)
- KE 55.89
- ATXS 29.58
- Support Level
- KE $17.69
- ATXS $7.29
- Resistance Level
- KE $19.20
- ATXS $7.95
- Average True Range (ATR)
- KE 0.56
- ATXS 0.42
- MACD
- KE 0.08
- ATXS -0.08
- Stochastic Oscillator
- KE 80.87
- ATXS 15.25
About KE Kimball Electronics Inc.
Kimball Electronics Inc is a contract electronic manufacturing services company. The company is engaged in producing durable electronics for the automotive, medical, industrial, and public safety end markets. The company's engineering, manufacturing, and supply chain services utilize common production and support capabilities. It is also engaged in producing safety-critical electronic assemblies for its automotive customers. Geographically, it has business units located in the United States, China, Mexico, Poland, Romania, and Thailand. The company derives maximum revenue from Mexico.
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.